Clinical trial of oral nelfinavir before and during radiation therapy for advanced rectal cancer

Clinical Cancer Research

Volumn 22, Issue 8, 2016, Pages 1922-1931

  Hill, Esme J ^a   Roberts, Corran ^a   Franklin, Jamie M ^a   Enescu, Monica ^b   West, Nicholas ^c   MacGregor, Thomas P ^a   Chu, Kwun Ye ^a   Boyle, Lucy ^a   Blesing, Claire ^d   Wang, Lai Mun ^d   Mukherjee, Somnath ^a   Anderson, Ewan M ^d   Brown, Gina ^e   Dutton, Susan ^a   Love, Sharon B ^a   Schnabel, Julia A ^b   Quirke, Phil ^c   Muschel, Ruth ^a   McKenna, William G ^a   Partridge, Michael ^a   Sharma, Ricky A ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d CHURCHILL HOSPITAL   (United Kingdom)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; K RAS PROTEIN; NELFINAVIR; BIOLOGICAL MARKER; RADIOSENSITIZING AGENT;

ADULT; ADVANCED CANCER; AGED; ALLERGIC RASH; ARTICLE; CANCER RADIOTHERAPY; CELL DENSITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG SAFETY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; GENE MUTATION; GLUCOSE BLOOD LEVEL; HEMORRHOID; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPONATREMIA; LYMPHOCYTOPENIA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE K RAS; OUTCOME ASSESSMENT; PAIN; PATIENT COMPLIANCE; PERFUSION; PERIANAL PAIN; PRIORITY JOURNAL; RADIOSENSITIZATION; RECTUM CANCER; TREATMENT DURATION; TUMOR BIOPSY; TUMOR BLOOD FLOW; TUMOR CELL; TUMOR PERFUSION; TUMOR REGRESSION; VOMITING; CANCER STAGING; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; RECTAL NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; BIOMARKERS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NELFINAVIR; NEOPLASM METASTASIS; NEOPLASM STAGING; RADIATION-SENSITIZING AGENTS; RECTAL NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84966293205     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1489     Document Type: Article

References (46)

1. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-46.
2. Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009;373:811-20.
3. Theodoropoulos G, Wise WE, Padmanabhan A, Kerner BA, Taylor CW, Aguilar PS, et al. T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 2002;45:895-903.
4. Bouzourene H, Bosman FT, Seelentag W, Matter M, Coucke P. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 2002;94:1121-30.
5. Vironen J, Juhola M, Kairaluoma M, Jantunen I, Kellokumpu I. Tumour regression grading in the evaluation of tumour response after different preoperative radiotherapy treatments for rectal carcinoma. Int J Colorectal Dis 2005;20:440-5.
6. Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol 2014;32:513-8.
7. van Dijk TH, Tamas K, Beukema JC, Beets GL, Gelderblom AJ, de Jong KP, et al. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. Ann Oncol 2013;24:1762-9.
8. Bonner JA, De Los Santos J, Waksal HW, Needle MN, Trummel HQ, Raisch KP. Epidermal growth factor receptor as a therapeutic target in head and neck cancer. Semin Radiat Oncol 2002;12:11-20.
9. McKenna WG, Weiss MC, Bakanauskas VJ, Sandler H, Kelsten ML, Biaglow J, et al. The role of the H-ras oncogene in radiation resistance and metastasis. Int J Radiat Oncol Biol Phys 1990;18:849-59.
10. Rosser CJ, Tanaka M, Pisters LL, Tanaka N, Levy LB, Hoover DC, et al. Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2- expressing prostate cancer cells to radiation. Cancer Gene Ther 2004; 11:273-9.
11. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R, et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002; 8:885-92.
12. Grana TM, Rusyn EV, Zhou H, Sartor CI, Cox AD. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signalregulated kinase kinase-independent signaling pathways. Cancer Res 2002;62:4142-50.
13. Gupta AK, Bakanauskas VJ, McKenna WG, Bernhard EJ, Muschel RJ. Ras regulation of radioresistance in cell culture. Methods Enzymol 2001;333: 284-90.
14. Kim IA, Fernandes AT, Gupta AK, McKenna WG, Bernhard EJ. The influence of Ras pathway signaling on tumor radiosensitivity. Cancer Metastasis Rev 2004;23:227-36.
15. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
16. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
17. Gupta AK, Cerniglia GJ, Mick R, McKenna WG, Muschel RJ. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res 2005;65:8256-65.
18. Qayum N, Muschel RJ, Im JH, Balathasan L, Koch CJ, Patel S, et al. Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res 2009;69:6347-54.
19. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7.
20. O'Connor JP, Rose CJ, Jackson A, Watson Y, Cheung S, Maders F, et al. DCEMRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. Br J Cancer 2011;105:139-45.
21. Bellomi M, Petralia G, Sonzogni A, Zampino MG, Rocca A. CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience. Radiology 2007;244:486-93.
22. de Vries A, Griebel J, Kremser C, Judmaier W, Gneiting T, Debbage P, et al. Monitoring of tumor microcirculation during fractionated radiation therapy in patients with rectal carcinoma: preliminary results and implications for therapy. Radiology 2000;217:385-91.
23. Janssen MHM, Aerts HJWL, Kierkels RGJ, Backes WH, Ollers MC, Buijsen J, et al. Tumor perfusion increases during hypofractionated short-course radiotherapy in rectal cancer: sequential perfusion-CT findings. Radiother Oncol 2010;94:156-60.
24. Sahani DV, Kalva SP, Hamberg LM, Hahn PF, Willett CG, Saini S, et al. Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology 2005;234: 785-92.
25. Kierkels RGJ, Backes WH, Janssen MHM, Buijsen J, Beets-Tan RGH, Lambin P, et al. Comparison between perfusion computed tomography and dynamic contrast-enhanced magnetic resonance imaging in rectal cancer. Int J Radiation Oncol Biol Phys 2010;77:400-8.
26. Hill EJ, Nicolay NJ, Middleton MR, Sharma RA. Oxaliplatin as a radiosensitiser for upper and lower gastrointestinal tract malignancies: what have we learned from a decade of translational research?Crit Rev Oncol/ Hematol 2012;83:353-87.
27. West NP, Dattani M, McShane P, Hutchins G, Grabsch J, Mueller W, et al. The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients. Br J Cancer 2010;102:1519-23.
28. West NGH, Treanor D, Sebag-Montefiore D, Thorpe H, Jayne D, Rutten H, et al. Quantitative assessment of tumour cell density in rectal cancer following three pre-operative therapies compared to surgery alone. J Clin Oncol 2010;28:3651.
29. Brunner T, Geiger M, Grabenbauer GG, Lang-Welzenbach M, Mantoni TS, Cavallaro A, et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2008;26:2699-706.
30. Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 2011;29:3753-60.
31. Nilsson PJ, van Etten B, Hospers GA, Pahlman L, van de Velde CJ, Beets-Tan RG, et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer-the RAPIDO trial. BMC Cancer 2013;13:279.
32. Buijsen J, Lammering G, Jansen RL, Beets GL, Wals J, Sosef M, et al. Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer. Radiother Oncol 2013;107:184-8.
33. Alonso-Basanta M, Fang P, Maity A, Hahn SM, Lustig RA, Dorsey JF. A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme. J Neurooncol 2014;116:365-72.
34. Hatfield P, Hingorani M, Radhakrishna G, Cooper R, Melcher A, Crellin A, et al. Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol 2009;92:210-4.
35. Pettersson D, Cedermark B, Holm T, Radu C, Pahlman L, Glimelius B, et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 2010;97:580-7.
36. Radu C, Berglund A, Pahlman L, Glimelius B. Short-course preoperative radiotherapy with delayed surgery in rectal cancer - a retrospective study. Radiother Oncol 2008;87:343-9.
37. Goh V, Halligan S, Gartner L, Bassett P, Bartram CI. Quantitative colorectal cancer perfusion measurement by multidetector-row CT: does greater tumour coverage improve measurement reproducibility?Br J Radiol 2006;79:578-83.
38. Goh V, Halligan S, Hugill JA, Bartram CI. Quantitative assessment of tissue perfusion using MDCT: comparison of colorectal cancer and skeletal muscle measurement reproducibility. AJR Am J Roentgenol 2006;187: 164-9.
39. Morgan B, Utting JF, Higginson A, Thomas AL, Steward WP, Horsfield MA. A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging. Br J Cancer 2006;94: 1420-7.
40. Lankester KJ, Taylor JN, Stirling JJ, Boxall J, d'Arcy JA, Collins DJ, et al. Dynamic MRI for imaging tumor microvasculature: comparison of susceptibility and relaxivity techniques in pelvic tumors. J Magn Reson Imaging 2007;25:796-805.
41. Kim JH, Kim CK, Park BK, Park SY, Huh SJ, Kim B. Dynamic contrastenhanced 3-T MR imaging in cervical cancer before and after concurrent chemoradiotherapy. Eur Radiol 2012;22:2533-9.
42. Lim JS, Kim D, Baek SE, Myoung S, Choi J, Shin SJ, et al. Perfusion MRI for the prediction of treatment response after preoperative chemoradiotherapy in locally advanced rectal cancer. Eur Radiol 2012;22:1693-700.
43. de Lussanet QG, Backes WH, Griffioen AW, Padhani AR, Baeten CI, van Baardwijk A, et al. Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int J Radiat Oncol Biol Phys 2005;63:1309-15.
44. Curvo-Semedo L, Portilha MA, Ruivo C, Borrego M, Leite JS, Caseiro-Alves F. Usefulness of Perfusion CT to Assess Response to Neoadjuvant Combined Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer. Acad Radiol 2012;19:203-13.
45. Huijbers A, Tollenaar RA, van Pelt GW, Zeestraten EC, Dutton S, McConkey CC, et al. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann Oncol 2013;24:179-85.
46. Rengan R, Mick R, Pryma D, Rosen MA, Lin L, Maity A, et al. et al.A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response. J Thorac Oncol 2012;7: 709-15.